Print

Multispan, Inc. and Promega Corporation to Streamline GPCR Drug Screening Programs  
1/9/2008 9:21:48 AM

MADISON, Wis.--(BUSINESS WIRE)--Today Multispan and Promega agreed to co-develop assay tools for G-protein coupled receptor (GPCR) screening. The companies will combine Multispan GPCR cell lines and Promega bioluminescent technologies to create novel optimized GPCR screening protocols. The first tools will support cell lines and cAMP-Glo™ Assay for quantification of signal. Additional tools will be developed for cell-based assay detection.
//-->